Triple Analysis: Leukemia, Lung Cancer and Apoptosis

News provided by

Aug 04, 2011, 04:51 ET

NEW YORK, Aug. 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0284941/Triple-Analysis-Leukemia-Lung-Cancer-and-Apoptosis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia

The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Lung Cancer

The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.

This part is based on the following publication:

Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part III: Apoptosis

The apoptosis report part comprises defined and up to date development strategies for 171 apoptotic drugs in oncology (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. This report part extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target strategies, and assesses them in 53 different cancer indications.

This part is based on the following publication:

Apoptotic Therapeutics in Oncology - Where to Commercialize?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia

5.1 The Scope of this Report 29

6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443

7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727

8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728

9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129

11 Disclaimer 1130

12 Drug Index 1131

13 Company Index 1140

Figures: Includes 6 Figures

Tables: Includes 253 Tables

Total Number of Pages: 1,147

Part II: Lung Cancer

5.1 The Scope of this Report 31

6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526

7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817

8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870

9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299

11 Disclaimer 1300

12 Drug Index 1301

13 Company Index 1314

Figures: Includes 7 Figures

Tables: Includes 284 Tables

Total Number of Pages: 1323

Part III: Apoptosis

5.1 The Scope of this Report 27

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (146 Drug Targets) 32-276

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline? (120 Drug Target Strategies and 171 Drugs) 277-311

8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type (7 Different Compound Strategies) 312-355

9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer Indications) 356-440

10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator (125 Investigators) 441-793

12 Drug Index 794

13 Company Index 799

Figures: Includes 6 Figures

Tables: Includes 248 Tables

Total Number of Pages: 803

To order this report:

Pathology Industry: Triple Analysis: Leukemia, Lung Cancer and Apoptosis

Pathology Business News

More Market Research Report